Governance Directors Remuneration Report Directors emoluments for the year audited Taxable Taxable Date of Appointment Fees Expenses Total Fees Expenses Total to the Board 2017 2017 2017 2016 2016 2016 Sir Martin Smith 8 November 2007 43,650 655 44,305 43,200 781 43,981 Humphrey Van Der Klugt 15 February 2016 30,685 386 31,071 3,430 3,430 Sarah Bates 22 May 2013 27,570 27,570 27,300 27,300 Dr David Holbrook 8 November 2007 28,670 50 28,720 27,300 125 27,425 Samuel D. Isaly 14 February 1995 27,570 27,570 27,300 27,300 Doug McCutcheon 7 November 2012 27,570 27,570 27,300 27,300 Jo Dixon 25 February 2004 16,055 1,183 17,238 33,450 2,298 35,748 Directors Fees 201,770 2,274 204,044 189,280 3,204 192,484 Taxable expenses primarily comprise travel and associated expenses incurred by the Directors in attending Board and Committee meetings in London.
These are reimbursed by the Company and, under HMRC Rules, are subject to tax and National Insurance and therefore are treated as a benefit in kind within this table.
Retired from the Board on 21September 2016.
In certain circumstances, under HMRC rules travel and Share price total return other out of pocket expenses reimbursed to the Directors The chart to the right illustrates the total shareholder return may be considered as taxable benefits.
Where expenses are for a holding in the Companys shares as compared to the classed as taxable under HMRC guidance, they are shown in Benchmark, which the Board has adopted as the key the taxable expenses column of the Directors remuneration measure of the Companys performance.
table along with the associated tax liability.
Total shareholder return for the eight years to No communications have been received from shareholders 31 March 2017 regarding Directors remuneration.
% 480 Sums paid to third parties 440 Until May 2016 fees due to Dr Holbrook were paid to MTI 400 Managers Limited, his then employer.
Thereafter, his fees 360 320 have been paid to him directly, otherwise none of the fees 280 referred to in the above table were paid to any third party in 240 respect of the services provided by any of the Directors.
200 160 Directors interests in the Companys shares 120 80 audited Mar-09 Mar-10 Mar-11 Mar-12 Mar-13 Mar-14 Mar-15 Mar-16 Mar-17 Ordinary Worldwide Healthcare Share Price total return Shares of 25p each Benchmark total return 2017 2016 Rebased to 100 as at March 2009 Source: Morningstar, Thomson Reuters and Bloomberg Sir Martin Smith 11,871 11,871 Trustee 2,725 2,725 Jo Dixon n a 3,859 Sarah Bates 7,200 7,200 Dr David Holbrook 1,094 1,094 Samuel D. Isaly 3,600 3,600 Humphrey van der Klugt 1,500 1,500 Doug McCutcheon 15,000 15,000 42,990 46,849 Retired from the Board on 21 September 2016 Worldwide Healthcare Trust PLC 44 Annual Report for the year ended 31 March 2017 Governance Directors Remuneration Report The bar chart below shows the comparative cost of Directors fees compared with the level of dividend distribution and ongoing charges for 2016 and 2017.
Relative cost of directors remuneration 11,000 10,000 9,000 8,000 7,000 6,000 5,000 4,000 3,000 2,000 1,000 0 Directors Dividends Ongoing Directors Dividends Ongoing Fees 2017 Charges Fees 2016 Charges 2017 2017 2016 2016 Annual statement On behalf of the Board, I confirm that the Directors Remuneration Policy, set out on page 43 of this Annual Report, and Directors Remuneration Report summarise, as applicable, for the year to 31 March 2017: a the major decisions on Directors remuneration: b any substantial changes relating to Directors remuneration made during the year: and c the context in which the changes occurred and decisions have been taken.
Doug McCutcheon Chairman of the Management Engagement & Remuneration Committee 14 June 2017 Worldwide Healthcare Trust PLC Annual Report for the year ended 31 March 2017 45 Governance Independent Auditors Report to the Members of Worldwide Healthcare Trust PLC We conducted our audit of the Report on the financial statements financial statements Our opinion usinginformation from the AIFM In our opinion, Worldwide Healthcare Trust PLCs financial and J. P. Morgan Europe Limited statements the financial statements : with whom the AIFM has engaged to give a true and fair view of the state of the Companys provide  affairs as at 31 March 2017 and of its profit for the year functions.
then ended: We tailored the scope of our audit have been properly prepared in accordance with United taking into account thetypes of Kingdom Generally Accepted Accounting Practice: and investments within the Company, have been prepared in accordance with the requirements the involvementof the third parties of the Companies Act 2006. referred to above, the accountingprocesses and controls, What we have audited and the industry in which The financial statements, included within the Annual Report, theCompany operates.
the Statement of Financial Position as at 31 March 2017: Valuation and existence of the Income Statement for the year then ended: investments.
the Statement of Changes in Equity for the year then Performance fees.
ended: and The scope of our audit and our areas of focus the notes to the financial statements, which include a We conducted our audit in accordance with International summary of significant accounting policies and other Standards on Auditing UK and Ireland ISAs UK & Ireland.
Certain required disclosures have been presented elsewhere We designed our audit by determining materiality and in the Annual Report, rather than in the notes to the assessing the risks of material misstatement in the financial financial statements.
These are cross-referenced from the statements.
In particular, we looked at where the Directors financial statements and are identified as audited.
made subjective judgements, for example in respect of significant accounting estimates that involved making The financial reporting framework that has been applied in assumptions and considering future events that are the preparation of the financial statements is United inherently uncertain.
As in all of our audits we also Kingdom Accounting Standards, comprising FRS 102 The addressed the risk of management override of internal Financial Reporting Standard applicable in the UK and controls, including evaluating whether there was evidence of Republic of Ireland, and applicable law United Kingdom bias by the Directors that represented a risk of material Generally Accepted Accounting Practice.
Our audit approach The risks of material misstatement that had the greatest effect on our audit, including the allocation of our resources Overview and effort, are identified as areas of focus in the table Materiality Overall materiality: 11,009,000 below.
We have also set out how we tailored our audit to which represents 1% of net assets.
address these specific areas in order to provide an opinion Audit Scope TheCompany is a standalone on the financial statements as a whole, and any comments Investment Trust Companyand we make on the results of our procedures should be read in engages Frostrow Capital LLP the this context.
This is not a complete list of all risks identified AIFM tomanage its assets.
Worldwide Healthcare Trust PLC 46 Annual Report for the year ended 31 March 2017 Governance Independent Auditors Report to the Members of Worldwide Healthcare Trust PLC Area of focus How our audit addressed the area of focus Income We assessed the accounting policy for income recognition Refer to pages 55 and 56 Accounting Policies and pages 58 for compliance with accounting standards and the AIC SORP and 62 Notes to the Financial Statements.
and performed testing to check that income had been accounted for in accordance with this stated accounting We focused on the accuracy and completeness of dividend policy.
income amounting to 13,098,000 for the year and its presentation in the Income Statement as set out in the We found that the accounting policies implemented were in requirements of The Association of Investment Companies accordance with accounting standards and the AIC SORP, Statement of Recommended Practice the AIC SORP.
and that income has been accounted for in accordance with the stated accounting policy.
We also focused on the calculation of realised and unrealised gains and losses on the investment amounting to We understood and assessed the design and implementation a gain of 260,256,000 for the year.
of key controls at JPMorgan CIB surrounding income recognition.
This is because incomplete or inaccurate income both revenue and capital could have a material impact on the In addition, we tested dividend income by agreeing the Companys net asset value.
dividend rates from a sample of investments to independent third party sources.
No misstatements were identified by our testing which required reporting to those charged with governance.
To test for completeness, we tested that the appropriate dividends had been received in the year by reference to independent data of dividends declared for a sample of investment holdings in the portfolio.
Our testing did not identify any unrecorded dividends.
We did not identify any special dividend income.
We have also tested the gains or losses on investments held at fair value comprising realised and unrealised gains or losses.
For realised gains or losses, we tested a sample of disposal proceeds to bank statements.
For unrealised gains or losses, we tested the valuation of the portfolio at the year-end, together with testing the reconciliation of opening and closing investments.
Worldwide Healthcare Trust PLC Annual Report for the year ended 31 March 2017 47 Governance Independent Auditors Report to the Members of Worldwide Healthcare Trust PLC Area of focus How our audit addressed the area of focus Valuation and existence of investments Quoted investments: Refer to page 41 Audit Committee Report, pages 55 and 56 We tested the valuation of quoted investments by agreeing Accounting Policies and page 62 Notes to the Financial the prices used to third party sources.
We tested the existence of the quoted investment portfolio The investment portfolio at 31 March 2017 principally by agreeing the holdings to an independent custodian comprised listed equity investments, OTC swaps and confirmation from J. P. Morgan Securities LLC.
No differences were identified which required reporting to We focused on the valuation and existence of investments those charged with governance.
because investments represent the principal element of the Unquoted debt investments: net asset value as disclosed on the Statement of Financial We tested the valuation of unquoted debt investments by Position in the financial statements.
agreeing the prices used to third party sources.
We tested the existence of the unquoted debt investments by agreeing the holdings for investments to an independent custodian confirmation.
No differences were identified which required reporting to those charged with governance.
OTC derivative financial instruments: We tested the valuation of the OTC derivatives by reperforming the valuation using independent market data.
We tested the existence of the OTC derivatives by agreeing the holdings to an independent confirmation from J. P. Morgan Securities LLC and the counterparty, Goldman Sachs International.
Performance fees We independently recalculated the performance fee using Refer to page 41 Audit Committee Report, page 56 the methodology set out in the AIFM Agreement and Accounting Policies and page 58 Notes to the Financial Portfolio Management Agreement and agreed the inputs to Statements.
the calculation, including the benchmark data, to independent third party sources, where applicable.
As at 31 March 2017, a performance fee accrual of 3.4m was calculated, all of which was recognised as a provision No misstatements were identified by our testing which for the potential future payment.
required reporting to those charged with governance.
Performance fees totalling 1.3m were paid during the year due to outperformance achieved for the quarter ending 30 September 2016.
This resulted in a total performance fee charge for the year of 4.7m.
We focused on this area because the performance fee is calculated using a complex methodology as set out in the AIFM Agreement and Portfolio Management Agreement.
Worldwide Healthcare Trust PLC 48 Annual Report for the year ended 31 March 2017 Governance Independent Auditors Report to the Members of Worldwide Healthcare Trust PLC How we tailored the audit scope Going concern We tailored the scope of our audit to ensure that we Under the Listing Rules we are required to review the performed enough work to be able to give an opinion on the Directors statement, set out on page 31, in relation to going financial statements as a whole, taking into account the concern.
We have nothing to report having performed our types of investments within the Company, the involvement of review.
the AIFM, the accounting processes and controls, and the Under ISAs UK & Ireland we are required to report to you if industry in which the Company operates.
we have anything material to add or to draw attention to in The Companys accounting is delegated to the AIFMwho relation to the Directors statement about whether they maintains the Companys accounting records and controls considered it appropriate to adopt the going concern basis in andreports to the Directors.
We have nothing material to add or to draw attention to.
Materiality As noted in the Directors statement, the Directors have The scope of our audit was influenced by our application of concluded that it is appropriate to adopt the going concern materiality.
We set certain quantitative thresholds for basis in preparing the financial statements.
These, together with qualitative considerations, concern basis presumes that the Company has adequate helped us to determine the scope of our audit and the resources to remain in operation, and that the Directors nature, timing and extent of our audit procedures on the intend it to do so, for at least one year from the date the individual financial statement line items and disclosures and financial statements were signed.
As part of our audit we in evaluating the effect of misstatements, both individually have concluded that the Directors use of the going concern and on the financial statements as a whole.
However, because not all future events Based on our professional judgement, we determined or conditions can be predicted, these statements are not a materiality for the financial statements as a whole as guarantee as to the Companys ability to continue as a going follows: concern.
How we determined it 1% of net assets.
Rationale for benchmark applied We have applied this benchmark, a generally accepted auditing practice for investment trust audits, in the absence of indicators that an alternative benchmark would be appropriate and because we believe this provides an appropriate and consistent year-on year basis for our audit.
We agreed with the Audit Committee that we would report to them misstatements identified during our audit above 550,000 2016: 441,000 as well as misstatements below that amount that, in our view, warranted reporting for qualitative reasons.
Worldwide Healthcare Trust PLC Annual Report for the year ended 31 March 2017 49
